Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer

　　Tepotinib is a highly selective MET tyrosine kinase inhibitor that has demonstrated significant clinical efficacy in the treatment of non-small cell lung cancer(NSCLC)harboring MET exon 14 skipping mutations,with a generally favorable safety profile.However,mild bleeding-related adverse reactions may still be observed in some patients receiving treatment.Therefore,during clinical medication,it is necessary to conduct individualized comprehensive assessment and full-course management of patients'bleeding risk.

　　Based on published clinical trial data and global real-world clinical observations,the vast majority of tepotinib-related bleeding events are mild,with the most common manifestations being epistaxis(nosebleeds)or skin ecchymosis(bruising),and the incidence of severe bleeding events is extremely low.The potential underlying mechanism may be related to the physiological role of the MET pathway in maintaining vascular endothelial cell integrity and tissue repair processes.When the MET signaling pathway is selectively inhibited by the drug,the stability of local microvessels may slightly decrease,but this effect usually does not lead to systemic coagulation dysfunction,which is an important reason why tepotinib-related bleeding is mostly local and mild.

　　In terms of bleeding risk stratification,the patient's baseline clinical status is the core factor determining the level of bleeding risk,rather than the inherent toxicity of the drug itself.The main high-risk factors include concurrent use of anticoagulant or antiplatelet drugs,underlying liver function impairment,and tumor lesions invading vascular structures.Among them,patients receiving anticoagulant or antiplatelet therapy may have their bleeding tendency further amplified by the drug effect,so more attention should be paid to individual differences and closer clinical monitoring is required in this population.

　　From a clinical manifestation perspective,most patients experience mild bleeding symptoms that resolve with symptomatic treatment and usually do not affect the continuity of treatment.However,in very rare cases,when a patient has multiple of the above high-risk factors simultaneously,relatively severe events such as gastrointestinal bleeding or respiratory tract bleeding may occur.It is particularly important to note that the occurrence of such severe bleeding events is often closely related to the location,size,and progression status of the tumor itself,rather than being solely caused by the drug effect.

　　From the perspective of overall safety comparison across drug classes,MET inhibitors as a class have a significantly lower overall bleeding risk than some anti-angiogenic targeted drugs,so tepotinib is not considered a high bleeding risk targeted therapy.Its safety profile depends more on the patient's underlying health status than on the direct toxic effects of the drug itself.

　　Overall,the inherent bleeding risk of tepotinib is low to moderate,and there is no need for universal excessive concern about bleeding risk in clinical practice.The core focus of clinical management is to comprehensively identify high-risk populations before treatment,develop individualized medication regimens,and conduct continuous clinical observation and monitoring during treatment to ensure the maximization of medication safety and therapeutic benefits.